Search - tctmd.com

Displaying 61 - 80 of 87

Sort: Relevancy | Date

News Daily News

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

L.A. McKeown

June 13, 2016

News Daily News

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

L.A. McKeown

June 13, 2016

News Conference News EAS 2016

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

Yael L. Maxwell

June 06, 2016

News Conference News ACC 2016

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

Michael O'Riordan

April 03, 2016

News Daily News

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Shelley Wood

February 16, 2016

News Industry News

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

February 04, 2016

News Features

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Michael O'Riordan

January 25, 2016

News Daily News

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Michael O'Riordan

December 15, 2015

News Daily News

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

Michael O'Riordan

December 15, 2015

News Daily News

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Michael O'Riordan

December 13, 2015

News Conference News AHA 2015

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

Yael L. Maxwell

November 08, 2015

News Industry News

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

October 20, 2015

News Industry News

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

September 28, 2015

News Industry News

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

September 11, 2015

News Industry News

FDA approves Repatha to treat certain patients with high cholesterol

August 28, 2015

News Industry News

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

August 20, 2015

News Industry News

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

July 24, 2015

News Industry News

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

July 21, 2015

News Industry News

FDA approves new antiplatelet drug used during heart procedure

June 24, 2015

Presentation TCT 2014

Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy

Presenter: Dietmar Trenk

September 16, 2014

Advertisement

CRP Can Identify Low CV Risk in Metabolically ‘Healthy’ Obese Patients

Los Niveles de CRP Puede Identificar Riesgos CV Bajos en Pacientes Obesos Metabólicamente ‘Sanos’

Preservation of LDL Cholesterol Targets for Lipid Lowering in New European Guidance Gets Blessing of Prevention Experts

Statin Intolerance and FH: GAUSS-3 Finds Benefit With Evolocumab, While Another Study Exposes Lifetime Risks of FH

FDA: No Cardiovascular Event Reduction Claim for Ezetimibe

Amgen Announces Positive Top-Line Results From Phase 3 GAUSS-3 Trial Of Repatha® (Evolocumab) In Statin-Intolerant Patients With High Cholesterol

PCSK9 Inhibitors: Good Early Responses With Pricey Drugs, but Doctors Still Waiting on Real Data

Ezetimibe Fails to Garner Support for CV- Event Reduction Claim From FDA Advisory Committee

Un Comité Asesor de la FDA No Avala la Afirmación de que Ezetimibe Reduce los Episodios CV

ACC, AHA Risk-Based Approach Remains Best Method for Statin Allocation in Primary Prevention

Knowing Genetic Risk for MI Motivates Patients, Physicians to Get Cholesterol Levels Lower

FDA approves Praxbind, the first reversal agent for the anticoagulant Pradaxa

Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union

Amgen Submits Application To FDA For New Delivery Option For Monthly Administration Of Repatha™ (Evolocumab)

FDA approves Repatha to treat certain patients with high cholesterol

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® Will Be Presented at the European Society of Cardiology

Regeneron and Sanofi Announce CHMP Recommends European Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia

European Commission Approves Amgen's New Cholesterol-Lowering Medication Repatha™ (evolocumab), The First PCSK9 Inhibitor To Be Approved In The World, For Treatment Of High Cholesterol

FDA approves new antiplatelet drug used during heart procedure

Antiplatelet Effects of Clopidogrel and Aspirin During 6 Months of Follow-up After Stent Implantation: An ADAPT-DES Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content